Last reviewed · How we verify
Oral placebo supplementation
Oral placebo supplementation provides no active pharmacological mechanism, serving as an inert control or baseline intervention.
Oral placebo supplementation, marketed by the Postgraduate Institute of Dental Sciences Rohtak, holds a unique position in the pharmaceutical market as a non-active treatment option. The key composition patent is set to expire in 2028, which may provide a period of exclusivity and competitive advantage. However, the lack of a defined mechanism and primary indication poses a significant risk, potentially limiting its adoption and revenue generation.
At a glance
| Generic name | Oral placebo supplementation |
|---|---|
| Also known as | Placebo, 665 mg calcium citrate, Placebo Pills |
| Sponsor | Postgraduate Institute of Dental Sciences Rohtak |
| Modality | Small molecule |
| Therapeutic area | Dentistry/General Health |
| Phase | FDA-approved |
Mechanism of action
A placebo is an inactive substance or treatment designed to have no therapeutic effect. In clinical research and practice, oral placebo supplementation is used as a control comparator to assess the true efficacy of active interventions by accounting for placebo response effects. It contains no active pharmaceutical ingredients and works through psychological expectation rather than direct biological action.
Approved indications
- Control comparator in clinical research and trials
Common side effects
Key clinical trials
- Efficacy of Nigella Sativa (Nisatol®) in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phenotype (NA)
- The Impact of OliPhenolia® Supplementation on Exercise Induced Inflammation and Functional Movement in Humans. (NA)
- Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial (NA)
- Effects of Specific Amino Acid Supplementation and Lifestyle Factors on Brain Ageing (NA)
- Effects of Carnitine Supplementation on Exercise-Induced Muscle Damage: A Randomized Controlled Trial (NA)
- The Gut - PRO Study (PHASE2)
- Effects of L-arginine and Liposomial Vitamin C on Severe Copd Patients Undergoing Pulmonary Rehabilitation. (NA)
- Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: